Machine Learning Assessment of Next-Day Migraine Likelihood

November 11, 2025 updated by: Theranica

Machine Learning Assessment Of Next-Day Migraine Likelihood Collected Via The Nerivio App

Development of a machine learning (ML) algorithm for assessment of next-day migraine likelihood, drawing on self-reported migraine-related information, and geographic location, collected via the Nerivio app- a mobile application used for migraine treatment by the Remote Electrical Neuromodulation (REN) wearable device.

Study Overview

Status

Completed

Conditions

Detailed Description

The analysis set includes patients with migraine who used Nerivio app for the reporting of migraine attacks and/or associated symptoms and/or migraine-related information.

Data collection is through the Nerivio app (Nerivio®). During app registration, patients consent to the collection of de-identified data for research purposes and provide demographic information. Participants can voluntarily report baseline characteristics such as treatment onset time relative to attack onset, headache pain, functional disability, and presence/absence of migraine-associated symptoms, as well as treatment outcomes 2-hours post-treatment. All data is stored on a HIPAA-compliant secure server.

The algorithm will be trained on user-level data. The dataset will be structured as a tabular matrix, where the columns represent risk-related features and the rows represent user-day observations. The feature set (X) serves as input variables, while the migraine occurrence label (Y) is the target outcome. The feature set (X) could be divided into four groups, according to the data source:

Demographic data - age and sex were self-reported via the app upon registration. The user's country is identified based on IP address.

Questionnaire data - features which are the patient's answers to either the daily diary questionnaire or a pre-treatment questionnaire. These include headache severity, functional disability, medication intake, aura, pain duration, and prodromal symptoms. Data on prodromal symptoms is collected via a multiple-choice question with 14 pre-defined answers.

Weather data - environmental features that are based on users' geographic location. These include barometric pressure, temperature, heat index, UV index, wind, humidity, and precipitation.

Calculated features - features that are calculated based on the aforementioned collected data. These include averages, frequencies, number of consecutive days, etc'.

Label (Y) Definition - The target variable (Y) will be defined using daily diary entries and pre-treatment questionnaires. The "next-day migraine" field served as the target outcome. A value of 1 (migraine day) will be assigned if a migraine was reported on the subsequent calendar day; a value of 0 (non-migraine day) will be assigned if no migraine was reported. Missing values were kept as null to capture potential information inherent in their non-random occurrence.

A day is classified as a migraine day (Y = 1) if both of the following conditions were met: A) Headache level was reported as mild, moderate, or severe in the diary or pre-treatment questionnaire. B) At least one additional migraine indicator was present: intake of migraine-related medication, or report of photophobia, phonophobia, nausea and/or vomiting, or aura in the diary or pre-treatment questionnaire.

The following standard ML outcome measures were used to evaluate model performance:

Precision- the percentage of migraine days correctly predicted, out of all predicted days.

Accuracy- the percentage of days correctly predicted (migraine and non-migraine), out of all the predicted days.

Sensitivity (also termed recall rate)- the percentage of migraine days correctly predicted, out of all the migraine days.

Specificity- the percentage of non-migraine days correctly predicted, out of all the non-migraine days.

Area Under the Curve (AUC)- the probability that the model ranks a migraine day higher than a non-migraine day, based on predicted risk scores (summarizing the model's ability to distinguish between migraine and non-migraine days across all classification thresholds).

F1 score- the balance between correctly predicted migraine days and avoiding wrongly-predicted migraine days, combining sensitivity and precision in one measure.

Study Type

Observational

Enrollment (Actual)

53065

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New Jersey
      • Bridgewater, New Jersey, United States, 08807
        • Theranica USA Inc

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Migraine patients that were prescribed and treated their migraine with the Nerivio device

Description

Inclusion Criteria:

  1. - Nerivio users age 8 and above.
  2. - Filled at least 2 daily diaries/ pre-treatment reports via the Nerivio app during the same month.

Exclusion Criteria:

  • NA

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Migraine patients who used the Nerivio device app
Nerivio users age 8 and above, who had filled at least 2 daily diaries or pre-treatment reports via the Nerivio app during the same month.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Precision of the prediction model
Time Frame: 24 hours
The percentage of migraine days correctly predicted, out of all predicted days.
24 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Specificity of the prediction model
Time Frame: 24 hours
The percentage of non-migraine days correctly predicted, out of all the non-migraine days
24 hours
Sensitivity of the prediction model
Time Frame: 24 hours
The percentage of migraine days correctly predicted, out of all the migraine days.
24 hours
Accuracy of the prediction model
Time Frame: 24 hours
The percentage of days correctly predicted (migraine and non-migraine), out of all the predicted days
24 hours
Area Under the Curve (AUC)
Time Frame: 24 hours
The probability that the model ranks a migraine day higher than a non-migraine day, based on predicted risk scores (summarizing the model's ability to distinguish between migraine and non-migraine days across all classification thresholds).
24 hours
F1 score for the prediction model
Time Frame: 24 hours
The balance between correctly predicted migraine days and avoiding wrongly-predicted migraine days, combining sensitivity and precision in one measure.
24 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Study Director: Liron Rabany, PhD, Theranica Bio-Electronics ltd

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 7, 2025

Primary Completion (Actual)

August 1, 2025

Study Completion (Actual)

August 20, 2025

Study Registration Dates

First Submitted

November 9, 2025

First Submitted That Met QC Criteria

November 11, 2025

First Posted (Actual)

November 12, 2025

Study Record Updates

Last Update Posted (Actual)

November 12, 2025

Last Update Submitted That Met QC Criteria

November 11, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Migraine

Subscribe